Received:31 July 2022 Revised:1 Rebruary 2023Accepted:12 February 2023D010.1111/ajd.14016Australasian lournl ofREVIEW ARTICLEDermatologyCD30-positive lymphoproliferative disorders-AnAustralian Clinical Practice Statement from the PeterMacCallum Cancer CentreFriyana K.Bhabha MBBS,FACD Christopher McCormack MBBS,FACDBelinda A.CampbellMBBS,MMed,FRANZCR23 Stephen Lade MBBS,FRCPAOdette Buelens RN,BN,PGDipNur(CancPall),MN,NPSCarrie Van Der Weyden MBBS(Hons)FRACP FRCPA5H.Miles Prince MBBS (Hons)MD FRACP FRCPA AFRCMA MACD FAHMSDepartment of Surgical Oncology,Peter MacCallum Cancer Centre,AbstractMelbourne,Victoria,AustraliaThe CD30-postive lymphoproliferative disorders,including lymphomatoid papu-Department of Radiation Oncology.losis and primary cutaneous anaplastic large cell lymphoma,account for up toPeter MacCallum Cancer Centre,Melbourne,Victoria,Australia30%of all cutaneous T-cell lymphomas (CTCLs)and are the second most com-Department of Clinical Pathology,Themon form of CTCLs after mycosis fungoides.Both conditions differ in their clini-University of Melbourne,Parkville,cal presentations;however,they share the expression of the CD30 antigen as aVictoria,Australiacommon immunophenotypic hallmark.There is a wide spectrum of management+Department of Pathology,PeterMacCallum Cancer Centre,Melbourne,options depending on factors such as extent of disease,staging and treatmentVictoria,Australiatolerability.This Clinical Practice Statement is reflective of the current clinicalSNurse Practitioner,Peter MacCallumpractice in Australia.Cancer Centre,Melbourne,Victoria,AustraliaKEYWORDSDepartment of Haematology,PeterCD30 lymphoproliferative disorders,cutaneous T cell lymphoma,lymphomatoid papulosis,MacCallum Cancer Centre,Melbourne,primary cutaneous anaplastic large cell lymphomaVictoria,AustraliaCorrespondenceFriyana K.Bhabha,Department ofSurgical Oncology,Peter MacCallumCancer Centre,Melbourne.Vic.3000.Australia.Email:friyana.bhabha@outlook.comINTRODUCTIONtheir clinical presentation.Both conditions have an excel-lent prognosis and represent a spectrum from the benignThe CD30-positive lymphoproliferative disorders(CD30+behaving condition of LyP through to primary cutaneousLPDs),including lymphomatoid papulosis (LyP)andanaplastic large cell lymphoma(C-ALCL).primary cutaneous anaplastic large cell lymphomaThe diagnosis of CD30+LPD is largely based on his-(C-ALCL),account for approximately 30%of all cases oftopathology.Adequate tissue is required for histopatho-all cutaneous T-cell lymphomas(CTCL).Both disorderslogical assessment.Excisional biopsy of small lesions,orshare the expression of the CD30 antigen as a commonincisional biopsy oflarger lesions,is preferred.In cosmeti-immunophenotypic hallmark;however,they differ incally sensitive sites,punch biopsy of 24mm is appropriate.Australas J Dermatol 202300:1-10.wileyonlinelibrary.com/journal/ajd2023 Australasian College of Dermatologists.1
